IGXBIO

igxbio-logo

IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.

#Financial #Website #More

IGXBIO

Industry:
Biotechnology Health Care Information Technology

Founded:
2001-01-01

Address:
Lenexa, Kansas, United States

Country:
United States

Website Url:
http://www.igxbio.com

Total Employee:
1+

Status:
Active

Contact:
(888)744-9246

Email Addresses:
[email protected]

Total Funding:
470 K USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Nginx PHP PHP 7 WordPress 6.0


Investors List

kansas-bioscience-authority_image

Kansas Bioscience Authority

Kansas Bioscience Authority investment in Seed Round - IGXBio

Official Site Inspections

http://www.igxbio.com

Unable to get host informations!!!

Loading ...

More informations about "IGXBio"

IGXBio - Crunchbase Company Profile & Funding

IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.See details»

Home - IGM Biosciences

Nov 8, 2024 IGM Biosciences is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody โ€ฆSee details»

IGXBio Company Profile 2025: Valuation, Funding & Investors

IGXBio General Information Description. Developer of advanced DNA immunotherapies created to target HIV infection. The company's therapeutics is a proprietary DNA composition that โ€ฆSee details»

IGM Biosciences - Crunchbase Company Profile & Funding

Organization. IGM Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โ€ฆSee details»

IGM Biosciences - Overview, News & Similar companies - ZoomInfo

Who is IGM Biosciences. About IGM Biosciences: Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating an d โ€ฆSee details»

About Us - IGM Biosciences

At IGM Biosciences, we believe that real innovation comes from looking beyond current approaches to envision a better way to address disease. Given the limitations of the widely โ€ฆSee details»

IGM Biosciences - Devex

Learn more about IGM Biosciences's jobs, projects, latest news, contact information and geographical presence. IGM Biosciences is pioneering a new class of antibody medicines for โ€ฆSee details»

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 โ€ฆ

Mar 27, 2023 MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on โ€ฆSee details»

Team Members Archive - IGM Biosciences

Dr. Harler joined IGM in 2021. She is our Chief Executive Officer and a member of our Board of Directors. Prior to joining IGM she was Senior Vice President, Head of Immunology and โ€ฆSee details»

IGM Biosciences to Host Conference Call and Webcast to Provide โ€ฆ

May 30, 2023 โ€“ Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET โ€“. MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a โ€ฆSee details»

IGM Biosciences Announces Strategic Pivot to Focus

Sep 30, 2024 โ€œWe also want to sincerely thank Chris for his leadership of the clinical development organization as it expanded beyond oncology. We wish each of them the best in โ€ฆSee details»

Strategic Pivot to Autoimmunity - IGM Biosciences

Imvotamab deeply depletes tissue-resident B cells in Non-Human Primates (NHPs) Non-human primate data presentations โ€ข 2023 American College of Rheumatology (ACR) Convergence โ€ฆSee details»

Elizabeth H.Z. Thompson, Ph.D. - IGM Biosciences

Dr. Thompson has served as a member of the board of California Life Sciences, a life sciences membership organization and was named to the PharmaVoice 100 list in 2023 and the โ€ฆSee details»

IGM Biosciences Announces Fourth Quarter and Full Year 2021 โ€ฆ

Mar 29, 2022 [email protected]. IGM Biosciences, Inc. Selected Statement of Operations Data (unaudited) (in thousands, except share and per share data) Three Months โ€ฆSee details»

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on ...

Sep 30, 2024 --IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline โ€ฆSee details»

2024-09-30 | IGM Biosciences Announces Strategic Pivot to

Sep 30, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology โ€ฆSee details»

Kim Michelson - IGM Biosciences

Prior to joining IGM, she served as Senior Vice President of Clinical Operations at Medpace, a global drug, biologic and medical device clinical research organization. Ms. Michelson has also โ€ฆSee details»

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare ...

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM โ€ฆSee details»

Structure, Function, and Therapeutic Use of IgM Antibodies

Time were being given arbitrary names, in 1964 the World Health Organization de๏ฌned a nomenclature system for antibody isotypes. As a consequence -macroglobulin was renamed โ€ฆSee details»

News Release - investor.igmbio.com

Apr 10, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and โ€ฆSee details»

linkstock.net © 2022. All rights reserved